GAMMA Investing LLC Has $962,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

GAMMA Investing LLC lifted its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK) by 3,824.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,928 shares of the company’s stock after buying an additional 30,140 shares during the period. GAMMA Investing LLC’s holdings in Scholar Rock were worth $962,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Amalgamated Bank lifted its stake in Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after purchasing an additional 620 shares during the last quarter. Global Retirement Partners LLC raised its holdings in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after acquiring an additional 766 shares during the period. Summit Investment Advisors Inc. raised its holdings in Scholar Rock by 16.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,109 shares of the company’s stock valued at $350,000 after acquiring an additional 1,170 shares during the period. Corebridge Financial Inc. raised its holdings in Scholar Rock by 5.2% in the 4th quarter. Corebridge Financial Inc. now owns 38,539 shares of the company’s stock valued at $1,666,000 after acquiring an additional 1,915 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in Scholar Rock in the 4th quarter valued at about $85,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Scholar Rock Stock Down 1.0%

Shares of SRRK opened at $32.13 on Tuesday. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The stock has a market capitalization of $3.05 billion, a PE ratio of -13.67 and a beta of 0.28. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm’s 50 day moving average is $31.06 and its 200-day moving average is $36.12.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter last year, the business posted ($0.59) EPS. Equities research analysts forecast that Scholar Rock Holding Co. will post -2.42 EPS for the current year.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, Director Jeffrey S. Flier sold 6,075 shares of the business’s stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $29.73, for a total transaction of $180,609.75. Following the sale, the director now owns 24,070 shares of the company’s stock, valued at approximately $715,601.10. The trade was a 20.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kristina Burow sold 5,400 shares of the business’s stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $29.72, for a total transaction of $160,488.00. Following the sale, the director now directly owns 21,071 shares in the company, valued at approximately $626,230.12. The trade was a 20.40% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,500 shares of company stock worth $1,181,671 over the last three months. Corporate insiders own 13.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on SRRK. Wedbush reissued an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a report on Wednesday, May 14th. Lifesci Capital raised shares of Scholar Rock to a “strong-buy” rating in a report on Tuesday, June 3rd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.